Cycloalkyl-substituted glutaramide antihypertensive agents
    1.
    发明授权
    Cycloalkyl-substituted glutaramide antihypertensive agents 失效
    环烷基取代戊二酰胺抗高血压药

    公开(公告)号:US4975444A

    公开(公告)日:1990-12-04

    申请号:US398675

    申请日:1989-08-25

    摘要: Compounds of the formula ##STR1## wherein A is a carbocyclic, saturated or unsaturated ring; R.sup.1 is hydrogen or alkyl; R and R.sup.4 are each alkyl, cycloalkyl, benzyl or a readily hydrolyzable ester group; Y is a bond or a straight or branch alkylene; R.sup.2 is hydrogen, aryl, heterocyclic, R.sup.6 CONR.sup.5, R.sup.7 NR.sup.5 CO, R.sup.7 NR.sup.5 SO.sub.2 --or R.sup.8 SO.sub.2 NR.sup.5 --where R.sup.5 is hydrogen, alkyl or aralkyl; R.sup.6 is alkyl, aryl, aralkyl, heterocyclic, heterocyclyalkyl or a group of the formula ##STR2## where R.sup.9 is hydrogen, hydroxy, alkoxy, alkyl, hydroxyalkyl, aralkyl, alkylene, heterocyclic, heterocyclylalkyl, R.sup.12 CONH--, R.sup.12 SO.sub.2 NH-- or (R.sup.13).sub.2 N--; R.sup.10 and R.sup.11 are each hydrogen or alkyl; or R.sup.10 is hydrogen and R.sup.11 is aminoalkyl, imidazolylmethyl, aryl, aralkyl, aralkoxyalkoxy, hydroxyalkyl or methylthioalkyl; or R.sup.10 and R.sup.11 together with the carbon to which they are attached form a carbocyclic or heterocyclic ring optionally substituted by amino, alkanoyl or aroyl; R.sup.12 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclic or heterocyclylalkyl; each R.sup.13 is hydrogen, alkyl, aralkyl or both R.sup.13 together with the nitrogen to which they are attached form a heterocyclic ring; R.sup.7 is alkyl, aryl, aralkyl, heterocyclic, heterocyclyalkyl or a group ##STR3## where R.sup.10 and R.sup.11 are as defined and R.sup.14 is (R.sup.13).sub.2 NCO, R.sup.12 OCH.sub.2 -- or R.sup.15 OCO, where R.sup.12 and R.sup.13 are as defined and R.sup.15 is alkyl, cycloalkyl or aralkyl; and R.sup.8 is alkyl, aryl, aralkyl, heterocyclic or heterocyclylalkyl; R.sup.3 is a group ##STR4## where R.sup.16 is hydrogen, halo, hydroxy, alkoxy, cycloalkoxy, alkenyloxy, alkoxycarbonyloxy, cycloalkoxycarbonylalkoxy or alkyl SO.sub.2 NH--; and R.sup.20 is hydrogen, alkyl, alkoxy, alkanoyl or halo; or R.sup.3 is 3-indolylmethyl or 3-indazolylmethyl, each optionally substituted in the benzenoid ring by alkyl, alkoxy, hydroxy or trifluoromethyl as antihypertensive agents.

    摘要翻译: 其中A是碳环,饱和或不饱和环的式IMA的化合物; R1是氢或烷基; R和R4各自为烷基,环烷基,苄基或易水解的酯基; Y是一个键或直链或支链亚烷基; R2是氢,芳基,杂环,R6CONR5,R7NR5CO,R7NR5SO2或R8SO2NR5,其中R5是氢,烷基或芳烷基; 其中R 9是氢,羟基,烷氧基,烷基,羟基烷基,芳烷基,亚烷基,杂环基,杂环基烷基,R 12 CONH-,R 12 SO 2 NH-或(R 13) 2N-; R 10和R 11各自为氢或烷基; 或R 10为氢,R 11为氨基烷基,咪唑基甲基,芳基,芳烷基,芳烷氧基烷氧基,羟基烷基或甲硫基烷基; 或R 10和R 11与它们所连接的碳一起形成任选被氨基,烷酰基或芳酰基取代的碳环或杂环; R 12是烷基,环烷基,芳基,芳烷基,杂环或杂环基烷基; 每个R 13是氢,烷基,芳烷基或两者R 13与它们所连接的氮一起形成杂环; R 7是烷基,芳基,芳烷基,杂环基,杂环烷基或基团,其中R 10和R 11如上所定义,R 14是(R 13)2 COCO,R 12 OCH 2或R 15 OCO,其中R 12和R 13如上定义,R 15是烷基,环烷基 或芳烷基; R8是烷基,芳基,芳烷基,杂环或杂环基烷基; R3是一个基团,其中R16是氢,卤素,羟基,烷氧基,环烷氧基,烯氧基,烷氧基羰氧基,环烷氧基羰基烷氧基或烷基SO2NH-; 和R 20是氢,烷基,烷氧基,烷酰基或卤素; 或R3是3-吲哚基甲基或3-吲唑基甲基,其各自任选在苯环中被烷基,烷氧基,羟基或三氟甲基取代作为抗高血压剂。

    Octahydro-6-azaindole compounds, compositions and use
    2.
    发明授权
    Octahydro-6-azaindole compounds, compositions and use 失效
    八氢-6-氮杂吲哚化合物,组合物和用途

    公开(公告)号:US4711882A

    公开(公告)日:1987-12-08

    申请号:US811253

    申请日:1985-12-19

    CPC分类号: C07K5/0222 A61K38/00

    摘要: A series of novel octahydro-6-azaindole dipeptide derivatives have been prepared, including their pharmaceutically acceptable salts and bioprecursors therefor. These particular compounds are inhibitors of the angiotensin converting enzyme and are therefore useful in therapy for the treatment of certain cardiovascular disorders, including heart failure and hypertension. Preferred member compounds include 1-[N-(1-S-ethoxycarbonyl-3-phenylpropyl)-S-alanyl]-2-S-carboxy-6-(N-methylcarbamoyl)-octahydro-6-azaindole, 1-[N-(1-S-ethoxycarbonyl-3-phenylpropyl-S-alanyl]-2-S-carboxy-6-methanesulphonyl-octahydro-6-azaindole and 1-[N-(1-carboxy-3-phenylpropyl)-S-lysyl]-2-carboxy-6-methanesulphonyl-octahydro-6-azaindole, respectively. Methods for preparing these compounds from known starting materials are provided.

    摘要翻译: 已经制备了一系列新的八氢-6-氮杂吲哚二肽衍生物,包括其药学上可接受的盐和生物前体。 这些特定化合物是血管紧张素转化酶的抑制剂,因此可用于治疗某些心血管疾病,包括心力衰竭和高血压。 优选的成员化合物包括1- [N-(1-S-乙氧基羰基-3-苯基丙基)-S-丙氨酰] -2-S-羧基-6-(N-甲基氨基甲酰基) - 八氢-6-氮杂吲哚,1- [ N-(1-S-乙氧基羰基-3-苯基丙基-S-丙氨酰基)-2-S-羧基-6-甲磺酰基 - 八氢-6-氮杂吲哚和1- [N-(1-羧基-3-苯基丙基) S-赖氨酰基] -2-羧基-6-甲磺酰基 - 八氢-6-氮杂吲哚,提供从已知原料制备这些化合物的方法。

    Process for preparing a S-trialkoxy benzene
    4.
    发明授权
    Process for preparing a S-trialkoxy benzene 失效
    制备S-三烷氧基苯的方法

    公开(公告)号:US4102933A

    公开(公告)日:1978-07-25

    申请号:US708025

    申请日:1976-07-23

    IPC分类号: C07C41/16 C07C41/04

    CPC分类号: C07C41/16

    摘要: A 1,3,5-trialkoxy benzene having 1-2 carbon atoms in each of the alkoxy-groups is prepared at high overall yields, with minimal formation of hazardous or polluting by-products, by reacting 1,3,5-tribromo benzene with an alkalimetal alcoholate having 1-3 carbon atoms in the molecule in the presence of a copper salt, e.g. cuprous iodide or cupric chloride, and an aprotic solvent such as e.g. dimethylformamide. The product is readily recovered from the reaction mixture in an overall yield as high as 90%.

    摘要翻译: 在每个烷氧基中具有1-2个碳原子的1,3,5-三烷氧基苯以高总收率制备,最小程度地形成有害或污染副产物,通过使1,3,5-三溴苯 在铜盐存在下,在分子中具有1-3个碳原子的碱金属醇化物,例如 碘化亚铜或氯化铜,以及非质子溶剂如 二甲基甲酰胺。 该产物容易从反应混合物中回收,总产率高达90%。